Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins.
about
Melanoma: new insights and new therapiesE2F1 in melanoma progression and metastasisTargeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cellsA survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy.Combining the endoplasmic reticulum stress-inducing agents bortezomib and fenretinide as a novel therapeutic strategy for metastatic melanomaMerkel cell carcinoma dependence on bcl-2 family members for survival.Melanoma proliferation and chemoresistance controlled by the DEK oncogeneOBATOCLAX and ABT-737 induce ER stress responses in human melanoma cells that limit induction of apoptosis.MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanomaProteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLsModulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner.The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells.ABT-737 synergizes with Bortezomib to kill melanoma cells.DARC: Mapping Surface Topography by Ray-Casting for Effective Virtual Screening at Protein Interaction Sites.Bcl-2 expression is not associated with survival in metastatic cutaneous melanoma: a historical cohort study.Analysis of changes in the proteome of HL-60 promyeloid leukemia cells induced by the proteasome inhibitor PSI.Phosphorylation of signal transducer and activator of transcription 1 reduces bortezomib-mediated apoptosis in cancer cells.Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effectsMcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists.Epac increases melanoma cell migration by a heparan sulfate-related mechanism.NMR strategy for unraveling structures of bioactive sponge-derived oxy-polyhalogenated diphenyl ethers.Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspectsTowards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review).Pharmacological Inhibition of Myocardin-related Transcription Factor Pathway Blocks Lung Metastases of RhoC-Overexpressing Melanoma.Altered mRNA expression related to the apoptotic effect of three xanthones on human melanoma SK-MEL-28 cell line.Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction.Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.Expression and function of bcl-2 proteins in melanomaProteasome inhibitors against amelanotic melanoma.Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells.Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy.BH3-only proteins: possible proapoptotic triggers for melanoma therapy.
P2860
Q26853127-CDFB2236-0B59-4D4C-AA54-725733083331Q28268420-591206DE-1203-4C75-B12B-2F9311747F3CQ33775637-59304FAE-2BEC-4C2C-A0C0-F2A0F6FC7583Q33833506-0F9029D3-8151-4FB3-B1A1-1D6E75E1B10CQ34051168-19578F0C-85DE-475E-A014-A246284039D2Q34273863-210A9B15-F87D-483A-AC30-5D3BCF26035DQ34997265-8E4EEC7F-0569-49B3-8A05-EB770973BCFBQ35075657-5B08D1A5-4FF1-4DD6-93BE-2A22373DE134Q35229253-82E37C80-50E5-4D23-A91F-243E00EE225EQ36028423-40B16719-B737-43CD-B5B6-B34F08DD231CQ36346964-2B053699-F059-4DD5-AF59-FCE183953A71Q36372909-B1B08BE1-9E80-4FEE-93AC-2B28EBDC1642Q36425600-3BDD917E-622A-4A86-906F-92D29CC61D68Q36447801-1E34812C-8BA0-4A59-A901-8E27546F15C4Q36782385-1988EDD4-2274-4F22-85C3-27F1B79F32F6Q36807352-BA26BF90-D2D0-4A47-8C82-5DAFFB6ED03CQ37073598-47704EC0-4CF8-493D-8DF7-3DB461A5302EQ37109324-DC991533-B7C8-494A-8ADF-DF5BB391FF0FQ37163339-79679C7E-2B11-47E6-BD0C-CD0C0FBE2032Q37406239-E2F986AD-8C68-4AAD-A71C-201EFED661ECQ37409403-C899061F-72E0-48AB-9C5D-741C228348C0Q37948056-D6B0BA83-65D6-4E1D-B78D-C8C3A6B87293Q38219616-0E393E41-87D5-4B65-8BF2-387D9936705CQ38731620-358C5381-15C1-4B94-BDA3-D790A3CBDB4DQ39068444-077B68F6-A1A3-4201-88AC-CF59750510E3Q39619870-4259499F-0964-4684-972D-447B13873B7BQ39958561-C0B7C43D-D176-40F1-9FDC-EDB7FF899EEAQ41941878-3A2848A2-A901-4504-A7EE-3DE461872726Q47141204-488BDC74-E650-4ADE-A141-32AD535EDD46Q48215818-926E1B07-7DF9-436C-8DAC-FBC4F381A4F9Q51746852-B68D7E62-2D87-4BFE-965C-2858E46D2FB9Q52878050-7589859F-2A3C-464F-AA4A-875F63AD0A38
P2860
Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Therapeutic window for melanom ...... proteasome on Bcl-2 proteins.
@en
type
label
Therapeutic window for melanom ...... proteasome on Bcl-2 proteins.
@en
prefLabel
Therapeutic window for melanom ...... proteasome on Bcl-2 proteins.
@en
P2093
P2860
P356
P1476
Therapeutic window for melanom ...... proteasome on Bcl-2 proteins.
@en
P2093
C Martin de la Vega
K G Wolter
M S Soengas
M Verhaegen
Y Fernández
Z Nikolovska-Coleska
P2860
P2888
P304
P356
10.1038/SJ.CDD.4402163
P577
2007-06-01T00:00:00Z
P5875
P6179
1009408982